KR20220147722A - 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 - Google Patents

항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 Download PDF

Info

Publication number
KR20220147722A
KR20220147722A KR1020227036943A KR20227036943A KR20220147722A KR 20220147722 A KR20220147722 A KR 20220147722A KR 1020227036943 A KR1020227036943 A KR 1020227036943A KR 20227036943 A KR20227036943 A KR 20227036943A KR 20220147722 A KR20220147722 A KR 20220147722A
Authority
KR
South Korea
Prior art keywords
antibody
subject
antigen
eoe
treatment
Prior art date
Application number
KR1020227036943A
Other languages
English (en)
Korean (ko)
Inventor
그렉 티모니
쉴라 구라티
로버트 피치
앨런 올슨
Original Assignee
애브비 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애브비 인코포레이티드 filed Critical 애브비 인코포레이티드
Priority to KR1020247011874A priority Critical patent/KR20240052871A/ko
Publication of KR20220147722A publication Critical patent/KR20220147722A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
KR1020227036943A 2016-04-27 2017-04-27 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 KR20220147722A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247011874A KR20240052871A (ko) 2016-04-27 2017-04-27 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662328539P 2016-04-27 2016-04-27
US62/328,539 2016-04-27
KR1020187034419A KR102460040B1 (ko) 2016-04-27 2017-04-27 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
PCT/US2017/029768 WO2017189805A1 (fr) 2016-04-27 2017-04-27 Méthodes de traitement de maladies dans lesquelles l'activité de l'il-13 est préjudiciable à l'aide d'anticorps anti-il-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187034419A Division KR102460040B1 (ko) 2016-04-27 2017-04-27 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247011874A Division KR20240052871A (ko) 2016-04-27 2017-04-27 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법

Publications (1)

Publication Number Publication Date
KR20220147722A true KR20220147722A (ko) 2022-11-03

Family

ID=60160091

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020247011874A KR20240052871A (ko) 2016-04-27 2017-04-27 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
KR1020227036943A KR20220147722A (ko) 2016-04-27 2017-04-27 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
KR1020187034419A KR102460040B1 (ko) 2016-04-27 2017-04-27 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020247011874A KR20240052871A (ko) 2016-04-27 2017-04-27 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187034419A KR102460040B1 (ko) 2016-04-27 2017-04-27 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법

Country Status (17)

Country Link
US (3) US11390669B2 (fr)
EP (2) EP4276108A3 (fr)
JP (4) JP6871948B2 (fr)
KR (3) KR20240052871A (fr)
CN (2) CN109562115A (fr)
AU (4) AU2017258097B2 (fr)
BR (1) BR112018072263A2 (fr)
CA (1) CA3021334C (fr)
DK (1) DK3448391T3 (fr)
EA (2) EA037960B1 (fr)
FI (1) FI3448391T3 (fr)
IL (2) IL297519B2 (fr)
LT (1) LT3448391T (fr)
MX (2) MX2018013172A (fr)
SG (1) SG11201809253RA (fr)
WO (1) WO2017189805A1 (fr)
ZA (2) ZA201807174B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3448391T (lt) * 2016-04-27 2024-06-25 AbbVie Manufacturing Management Unlimited Company Ligų, kurių atveju il-13 aktyvumas yra žalingas, gydymo būdas, panaudojant anti-il-13 antikūnus
US11136387B2 (en) 2016-05-18 2021-10-05 Shanghai Pharmaexplorer Co., Ltd. IL-13 antibody and preparation method and use thereof
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
EP3755432A4 (fr) * 2018-02-21 2021-12-01 Ellodi Pharmaceuticals, L.P. Méthode de traitement d'oesophagite à éosinophiles
CA3174431A1 (fr) * 2020-05-22 2021-11-25 Jennifer D. Hamilton Methodes de traitement de l'oesophagite a eosinophiles par administration d'un inhibiteur d'il-4r

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0478627A4 (en) 1989-05-16 1992-08-19 William D. Huse Co-expression of heteromeric receptors
CA2016842A1 (fr) 1989-05-16 1990-11-16 Richard A. Lerner Methode pour puiser dans le repertoire immunologique
CA2016841C (fr) 1989-05-16 1999-09-21 William D. Huse Methode de production de polymeres ayant une activite choisie
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DE122004000004I1 (de) 1996-02-09 2004-08-12 Abott Biotechnology Ltd Humane Antikörper welche an Humanen TNFalpha binden.
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
CA2407956A1 (fr) 2000-05-03 2001-11-08 Amgen Inc. Peptides modifies utilises comme agents therapeutiques
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
JP4063213B2 (ja) 2003-12-09 2008-03-19 カシオ計算機株式会社 光源装置及びそれを備えたプロジェクタ
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) * 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
RU2472807C2 (ru) 2006-09-08 2013-01-20 Эбботт Лэборетриз Интерлейкин-13-связывающие белки
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
HUE053489T2 (hu) * 2009-10-20 2021-06-28 Abbvie Inc Az anti-il-13 antitestek izolálása és tisztítása a protein A affinitás kromatográviával
SG189220A1 (en) 2010-10-06 2013-05-31 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
MX352789B (es) * 2010-12-16 2017-12-08 Genentech Inc Anticuerpo anti-il-13 para usarse en tratar un asma o un trastorno respiratorio.
EP2723899B1 (fr) 2011-06-21 2020-11-18 Children's Hospital Medical Center Méthodes de diagnostic pour oesophagite à éosinophiles
US9345763B2 (en) 2011-06-23 2016-05-24 Children's Hospital Medical Center Methods of treating allergic inflammatory conditions by administering an anti-cadherin-like 26-based therapeutic
CA2841970A1 (fr) * 2011-07-13 2013-01-17 Abbvie Inc. Methodes et compositions pour le traitement de l'asthme a l'aide d'anticorps anti-il-13
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
JP6715767B2 (ja) * 2013-10-23 2020-07-01 ジェネンテック， インコーポレイテッド 好酸球性疾患の診断及び治療方法
US10176301B2 (en) 2014-09-11 2019-01-08 Meritage Pharma, Inc. Systems, methods, and software for providing a patient-reported outcome measure of dysphagia patients with eosinophilic esophagitis
LT3448391T (lt) * 2016-04-27 2024-06-25 AbbVie Manufacturing Management Unlimited Company Ligų, kurių atveju il-13 aktyvumas yra žalingas, gydymo būdas, panaudojant anti-il-13 antikūnus
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Also Published As

Publication number Publication date
US20210380674A1 (en) 2021-12-09
CA3021334A1 (fr) 2017-11-02
EA037960B1 (ru) 2021-06-15
EP3448391A4 (fr) 2019-12-18
EP4276108A3 (fr) 2024-01-24
JP6871948B2 (ja) 2021-05-19
AU2017258097B2 (en) 2019-10-24
AU2019275659B2 (en) 2021-04-22
JP2019514919A (ja) 2019-06-06
MX2018013172A (es) 2019-02-21
JP2021050204A (ja) 2021-04-01
BR112018072263A2 (pt) 2019-02-12
WO2017189805A1 (fr) 2017-11-02
IL297519B1 (en) 2024-02-01
JP2022160627A (ja) 2022-10-19
JP7434456B2 (ja) 2024-02-20
US11390669B2 (en) 2022-07-19
SG11201809253RA (en) 2018-11-29
EA202190162A3 (ru) 2021-11-30
JP7124040B2 (ja) 2022-08-23
US20230220061A1 (en) 2023-07-13
AU2021203358B2 (en) 2022-12-01
CN109562115A (zh) 2019-04-02
EP3448391B1 (fr) 2024-05-29
KR20240052871A (ko) 2024-04-23
CA3021334C (fr) 2022-11-29
AU2019275659A1 (en) 2020-01-02
EP4276108A2 (fr) 2023-11-15
JP2024054237A (ja) 2024-04-16
ZA201807174B (en) 2021-06-30
CN114617962A (zh) 2022-06-14
ZA202000478B (en) 2021-10-27
MX2022008255A (es) 2022-08-04
IL262441A (en) 2018-12-31
KR102460040B1 (ko) 2022-11-01
DK3448391T3 (da) 2024-06-24
AU2022268294A1 (en) 2022-12-15
KR20190002607A (ko) 2019-01-08
EA202190162A2 (ru) 2021-04-30
EP3448391A1 (fr) 2019-03-06
IL262441B2 (en) 2023-06-01
US20220281968A1 (en) 2022-09-08
IL297519A (en) 2022-12-01
AU2021203358A1 (en) 2021-06-24
IL297519B2 (en) 2024-06-01
LT3448391T (lt) 2024-06-25
EA201892409A1 (ru) 2019-03-29
FI3448391T3 (fi) 2024-06-19
AU2017258097A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
AU2020200497B2 (en) Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitor
US20210363237A1 (en) Methods for treating active eosinophilic esophagitis
AU2021203358B2 (en) Methods of treatment of diseases in which IL-13 activity is detrimental using anti-IL-13 antibodies
JP2024016237A (ja) 活動性好酸球性食道炎を治療する方法
NZ786219A (en) Methods of treatment of diseases in which IL-13 activity is detrimental using anti-IL-13 antibodies
EA045955B1 (ru) Способы лечения заболеваний, при которых активность il-13 оказывает негативное влияние, с применением антител против il-13
JP2019069987A (ja) Ｉｌ−４ｒアンタゴニストの投与により鼻茸を処置する方法

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision